David Angulo

The Emerging Pathogen Candida auris: Growth Phenotype, Virulence Factors, Activity of Antifungals, and Effect of SCY-078, a Novel Glucan Synthesis Inhibitor, on Growth Morphology and Biofilm Formation

Emily L. Larkin, Christopher Hager, Jyotsna Chandra et al. · Antimicrobial Agents and Chemotherapy · 2017 · 393 citations · Full text

Life Sciences, Infectious Diseases, Microbiology +17

Preclinical Pharmacokinetics and Pharmacodynamic Target of SCY-078, a First-in-Class Orally Active Antifungal Glucan Synthesis Inhibitor, in Murine Models of Disseminated Candidiasis

Stephen A. Wring, Ryan Randolph, Seonghee Park et al. · Antimicrobial Agents and Chemotherapy · 2017 · 93 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +17

Pharmacokinetics of Oral Posaconazole in Neutropenic Patients Receiving Chemotherapy for Acute Myelogenous Leukemia or Myelodysplastic Syndrome

Gopal Krishna, Malaz Abutarif, Fengjuan Xuan et al. · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · 2008 · 89 citations

Medicine, Pharmacokinetics, Pharmacology +15

<i>De Novo</i> Acquisition of Resistance to SCY-078 in Candida glabrata Involves FKS Mutations That both Overlap and Are Distinct from Those Conferring Echinocandin Resistance

Cristina Jiménez‐Ortigosa, Winder B. Perez, David Angulo et al. · Antimicrobial Agents and Chemotherapy · 2017 · 88 citations · Full text

Life Sciences, Microbiology, Antimicrobial Resistance +16

SCY-078 Is Fungicidal against Candida Species in Time-Kill Studies

Bernard Scorneaux, David Angulo, Katyna Borroto–Esoda et al. · Antimicrobial Agents and Chemotherapy · 2017 · 87 citations · Full text

Medicine, Microbiology, Pharmacology +17